focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-EU to extend vaccine export curbs to cover Britain, backloading -source

Tue, 23rd Mar 2021 16:31

* EU Commission to propose tighter mechanism on Weds

* Even firms meeting quarterly supply contracts may be hit

* Export block to also hit states with higher shot rates

* J&J has signalled backloaded Q2 deliveries to EU
(Adds Prime Minister Boris Johnson)

By Francesco Guarascio

BRUSSELS, March 23 (Reuters) - The European Commission will
on Wednesday extend EU powers to potentially block COVID-19
vaccine exports to Britain and other areas with much higher
vaccination rates, and to cover instances of companies
backloading contracted supplies, an EU official said.

The moves, which the EU official said could hit Johnson &
Johnson, are designed to avoid even limited shortfalls
in deliveries to a region whose inoculation programme has been
beset by delays and supply issues.

Shipments abroad could also be withheld if vaccine-producing
countries, such as Britain and the United States, do not allow
exports to the EU, the official said, confirming comments by
Commission head Ursula von der Leyen last week.

As tensions between London and Brussels rose on Monday over
a possible export ban, Britain demanded that EU authorities
allow the delivery of COVID-19 vaccines it has ordered.

On Tuesday, Prime Minister Boris Johnson said Britain did
not believe in imposing vaccine blockades. "I'm encouraged by
some of the things I've heard from the continent in the same
sense," he told a news briefing.

Johnson & Johnson has announced delays in its supplies to
the EU in the second quarter, which the EU official said could
lead to consequences under the Commission amendment covering
companies backloading contracted quarterly deliveries.

All vaccine makers could potentially be affected, added the
official, who has direct knowledge of the Commission decision.

'WE DON'T WANT THE SAME DELAYS IN Q2'

The EU this month used an existing export control mechanism,
set up at the end of January, to block a shipment of AstraZeneca
vaccine to Australia.

That mechanism can at present be activated only if companies
do not meet contracted quarterly delivery targets. The
AstraZeneca exports were blocked after the company announced
steep cuts in first quarter deliveries to the EU.

With the amendments to be adopted on Wednesday, the EU will
however be able to block exports to cover companies that respect
their quarterly contracts but backload supplies to the end of
the period, said the official, who asked to remain anonymous.

Johnson & Johnson, which has committed to delivering 55
million doses to the EU between April and June, has said its
deliveries were likely to start in the second half of April
.

The company told EU officials it was facing production
issues that might make it difficult to meet its second quarter
target, but that was striving to fulfil it..

Moderna and Pfizer/BioNTech also
had delays in their vaccine delivery rollouts to the EU, though
they are set to meet their overall targets for the first
quarter.

"We don't want the same delays to happen in the second
quarter," said the official.

Any decision to bloc an export would however need to be
taken in agreement with the EU state from where the shipment
would leave the bloc, and take into account the overall stance
of a company and of the importing state. "We will balance things
out," the official said.

The new rules, which will take effect immediately after
publication in the EU official journal, will also tighten
controls to make sure export blocks are not circumvented using
third countries, the official said.

The U.S. administration told EU officials in March that it
would not allow any time soon the shipment to the EU of
AstraZeneca vaccines produced in the United States, EU officials
told Reuters.

(Reporting by Francesco Guarascio @fraguarascio; editing by
John Stonestreet)

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.